Can Movantik (methylnaltrexone) and Miralax (polyethylene glycol 3350) be taken together?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: May 26, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Yes, Movantik and Miralax can be taken together safely and may provide complementary benefits for managing opioid-induced constipation.

The combination is explicitly supported by clinical guidelines, which recommend adding polyethylene glycol (Miralax) as a second-line laxative when constipation persists despite initial therapy, and this can be used alongside peripherally acting mu-opioid receptor antagonists like Movantik (naloxegol). 1

How These Medications Work Together

Movantik (naloxegol) is a peripherally acting mu-opioid receptor antagonist (PAMORA) that specifically blocks opioid receptors in the gut without affecting pain control. It addresses the root cause of opioid-induced constipation by reversing the constipating effects of opioids at the intestinal level 2, 3.

Miralax (polyethylene glycol 3350) is an osmotic laxative that works by drawing water into the colon to soften stool and promote bowel movements through a completely different mechanism 4, 5.

Clinical Evidence for Combination Use

The NCCN Palliative Care guidelines specifically state that when constipation persists despite standard laxative therapy (which includes polyethylene glycol), peripherally acting mu-opioid receptor antagonists such as naloxegol should be considered 1. This sequential recommendation implies these agents can work together.

Additionally, the guidelines note that lubiprostone (another constipation agent) "could be used in combination with a peripherally acting μ-opioid receptor antagonist such as methylnaltrexone" 1, establishing precedent for combining PAMORAs with other laxative mechanisms.

Recommended Treatment Algorithm

  1. Start with standard laxatives first: Begin with stimulant laxatives (senna) with or without stool softeners, plus adequate fluid intake 1, 6

  2. Add osmotic laxatives if needed: If constipation persists, add polyethylene glycol (Miralax) 1 capful in 8 oz water twice daily, along with bisacodyl, lactulose, or magnesium-based products 7, 1

  3. Add Movantik for refractory cases: When response to laxative therapy remains insufficient for opioid-induced constipation, add naloxegol 25 mg once daily (or 12.5 mg if taking moderate CYP3A4 inhibitors) 2, 3

Important Safety Considerations

No drug interactions exist between these medications. The FDA label for Movantik confirms that naloxegol does not significantly inhibit or induce the enzymes that would affect other medications, and polyethylene glycol is not metabolized systemically 3.

Timing considerations:

  • Take Movantik on an empty stomach at least 1 hour before the first meal or 2 hours after the meal 3
  • Miralax can be taken at any time and mixed with any beverage
  • Space them apart during the day for practical purposes, though not required

Common pitfalls to avoid:

  • Do not use Movantik if bowel obstruction is suspected or confirmed 1
  • Avoid grapefruit juice while taking Movantik, as it increases naloxegol levels 3
  • Do not combine Movantik with strong CYP3A4 inhibitors (ketoconazole, clarithromycin, itraconazole) 3
  • Monitor for opioid withdrawal symptoms when starting Movantik, though this is rare with peripheral antagonists 8

Expected Outcomes

With Miralax alone, approximately 78% of patients achieve treatment success for medication-induced constipation 4. When adding Movantik for laxative-refractory opioid-induced constipation, approximately 52% achieve at least 3 spontaneous bowel movements per week compared to 35% with placebo 2.

The combination addresses constipation through two complementary mechanisms—reversing opioid effects at the gut level while simultaneously increasing stool water content—making it a rational and guideline-supported approach for difficult-to-treat opioid-induced constipation.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.